相似文献
1
Nomifensine in parkinsonism.
J Neurol Neurosurg Psychiatry. 1976 Dec;39(12):1219-21. doi: 10.1136/jnnp.39.12.1219.
2
Nomifensine: effect in Parkinsonian patients not receiving levodopa.
J Neurol Neurosurg Psychiatry. 1981 Apr;44(4):352-4. doi: 10.1136/jnnp.44.4.352.
3
Nomifensine in parkinsonism.
Br J Clin Pharmacol. 1977;4Suppl 2(Suppl 2):185S-186S. doi: 10.1111/j.1365-2125.1977.tb05750.x.
4
Nomifensine in Parkinson's disease.
Br J Clin Pharmacol. 1977;4Suppl 2(Suppl 2):187S-190S. doi: 10.1111/j.1365-2125.1977.tb05751.x.
5
Dopaminergic agonist Ro 8-4650 in Parkinson's disease. I. Patients treated with dopa.
Acta Neurol Scand. 1978 Jul;58(1):74-6. doi: 10.1111/j.1600-0404.1978.tb02862.x.
6
Sodium valproate in the treatment of levodopa-induced dyskinesia.
J Neurol Neurosurg Psychiatry. 1978 Aug;41(8):702-6. doi: 10.1136/jnnp.41.8.702.
7
Dopaminergic agonist Ro 8-4650 in Parkinson's disease. II. Patients not treated with dopa.
Acta Neurol Scand. 1978 Jul;58(1):77-9. doi: 10.1111/j.1600-0404.1978.tb02863.x.
8
Comparison of the antidepressant action of tryptophan, tryptophan/5-hydroxytryptophan combination and nomifensine.
Neuropsychobiology. 1984;11(2):111-5. doi: 10.1159/000118063.
9
Bromocriptine in Parkinsonism.
Br Med J. 1974 Nov 23;4(5942):442-4. doi: 10.1136/bmj.4.5942.442.
10
Baclofen in Parkinson's disease.
J Neurol Neurosurg Psychiatry. 1978 Aug;41(8):707-8. doi: 10.1136/jnnp.41.8.707.
引用本文的文献
1
Experimental Dopamine Reuptake Inhibitors in Parkinson's Disease: A Review of the Evidence.
J Exp Pharmacol. 2021 Mar 29;13:397-408. doi: 10.2147/JEP.S267032. eCollection 2021.
2
Monoamine reuptake inhibitors in Parkinson's disease.
Parkinsons Dis. 2015;2015:609428. doi: 10.1155/2015/609428. Epub 2015 Feb 25.
3
Nomifensine: effect in Parkinsonian patients not receiving levodopa.
J Neurol Neurosurg Psychiatry. 1981 Apr;44(4):352-4. doi: 10.1136/jnnp.44.4.352.
4
Nomifensine in Parkinson's disease.
Br J Clin Pharmacol. 1977;4Suppl 2(Suppl 2):187S-190S. doi: 10.1111/j.1365-2125.1977.tb05751.x.
5
Nomifensine in parkinsonism.
Br J Clin Pharmacol. 1977;4Suppl 2(Suppl 2):185S-186S. doi: 10.1111/j.1365-2125.1977.tb05750.x.
本文引用的文献
1
8-Amino-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline, a new antidepressant.
Arzneimittelforschung. 1973 Jan;23(1):45-50.
2
Effect of nomifensine (HOE 984), a new antidepressant, on uptake of noradrenaline and serotonin and on release of noradrenaline in rat brain synaptosomes.
Biochem Pharmacol. 1974 Dec 15;23(24):3413-22. doi: 10.1016/0006-2952(74)90344-x.
3
Bromocriptine in Parkinsonism.
Br Med J. 1974 Nov 23;4(5942):442-4. doi: 10.1136/bmj.4.5942.442.
4
Effect of nomifensine on motor activity, dopamine turnover rate and cyclic 3',5;-adenosine monophosphate concentrations of rat striatum.
Naunyn Schmiedebergs Arch Pharmacol. 1974;286(1):49-63. doi: 10.1007/BF00499104.
5
Actions of dopaminergic agonists on motor function.
Adv Neurol. 1975;9:285-97.
6
Nomifensine: a potent dopaminergic agonist of antiparkinson potential.
Psychopharmacologia. 1975;41(2):153-64. doi: 10.1007/BF00421073.
Zotero 插件